Comprehensive analysis of autoantibodies in autoimmune hepatitis using proteomics tool

利用蛋白质组学工具综合分析自身免疫性肝炎中的自身抗体

• 批准号: 21590854
• 负责人: OHIRA Hiromasa
• 金额: $ 2.5万
• 依托单位: Fukushima Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21590854/
• 关键词: プロテオソーム; 自己免疫性肝炎; phosphoenolpyruvate carboxykinase; 自己抗体; PEPCK; 原発性胆汁性肝硬変; プロテオーム; 臨床; 免疫学

In this study, we analyzed autoantibodies in patients with autoimmune hepatitis(AIH) using proteomics tool. In the process of screening of autoantibodies, phosphoenolpyruvate carboxykinase(PEPCK) protein was identified as a target antigen of an autoantibody from serum of patients with AIH. Anti-PEPCK antibody was positive in 33. 3%(10/30) in patients with AIH, 43. 7%(7/16) in patients with primary biliary cirrhosis(PBC)-AIH overlap and 6%(2/30) in patients with PBC, but not detected in healthy control. This antibody is detected by high frequency in AIH patients and its specificity is high. In conclusion, measurement of anti-PEPCK antibody is considered to be useful for diagnosis of autoimmune hepatitis.

本研究利用蛋白质组学技术分析自身免疫性肝炎（AIH）患者的自身抗体。在自身抗体的筛选过程中，磷酸烯醇式丙酮酸羧激酶（PEPCK）蛋白被鉴定为来自AIH患者血清的自身抗体的靶抗原。抗PEPCK抗体阳性33例。3%（10/30），AIH组43。原发性胆汁性肝硬化（PBC）与AIH重叠者7%（7/16），PBC组6%（2/30），而健康对照组未检出。该抗体在AIH患者中检出率高，特异性强。结论：抗PEPCK抗体的测定对自身免疫性肝炎的诊断是有用的。